Search Results

Adaptive Phage Therapeutics is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.

Beyond Air, Inc. announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to license the commercial rights for multiple neuronal nitric oxide synthase inhibitor candidates, currently being developed for the treatment of autism spectrum disorder and other neurological conditions.

Clearmind Medicine Inc. announced the successful completion of two R&D projects with leading scientists from multiple disciplines at the Hebrew University as part of a collaboration established with the university’s technology transfer company, Yissum.

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”) announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”) announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem, earlier this week.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem.

Tarsier Pharma Ltd. announced the publication of a review article authored by Dr. Vofo and Prof. Chowers, an AMD expert serving as the chairman of the Division of Ophthalmology at Hadassah Hebrew University Medical Center, Jerusalem, Israel .

Edgewood Oncology announced the publication of new preclinical data from a study of BTX-A51 in human liposarcoma conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School to be presented at the AACR Annual Meeting 2024 in San Diego.